BridgeBio Pharma, Inc. (BIT:1BBIO)
Italy · Delayed Price · Currency is EUR | Market Cap | 13.48B +64.0% |
| Revenue (ttm) | 624.15M +202.4% |
| Net Income | -605.59M |
| EPS | -3.12 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 307 |
| Open | 68.85 |
| Previous Close | 71.20 |
| Day's Range | 68.85 - 68.85 |
| 52-Week Range | 40.93 - 80.42 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 10, 2026 |
About BridgeBio Pharma
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective ... [Read more]
Financial Performance
In 2025, BridgeBio Pharma's revenue was $502.08 million, an increase of 126.26% compared to the previous year's $221.90 million. Losses were -$724.93 million, 35.3% more than in 2024.
Financial numbers in USD Financial StatementsNews
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
- The transaction supports the evolution of the Company's shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. ...
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines fo...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
BridgeBio Pharma Earnings Call Transcript: Q2 2026
Q2 saw robust revenue growth, led by Attruby's clinical differentiation and expanding first-line share. Three late-stage programs advanced to regulatory review, with two receiving priority status, and a $1B equity raise strengthened the balance sheet for upcoming launches.
BridgeBio Pharma Earnings release: Q2 2026
BridgeBio Pharma released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
BridgeBio Pharma Quarterly report: Q2 2026
BridgeBio Pharma has published its Q2 2026 quarterly earnings report on August 10, 2026.
BridgeBio Pharma Slides: Corporate presentation
BridgeBio Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
PALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1 , representing a potential blockb...
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (...
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% pr...
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically sig...
BridgeBio Pharma Slides: Conference presentation
BridgeBio Pharma has posted slides in relation to its latest quarterly earnings report, which was published on June 28, 2026.
BridgeBio Pharma Transcript: AGM 2026
The meeting covered director elections, executive compensation, auditor ratification, and stock plan amendments, with all proposals approved by majority vote. No questions were raised by stockholders, and voting results will be filed with the SEC.
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on develo...
BridgeBio Pharma Transcript: Jefferies Global Healthcare Conference 2026
The session highlighted robust growth for Attruby, driven by clinical differentiation and strong market uptake, with three late-stage products nearing launch. Pipeline programs target rare genetic diseases with significant pricing power and expansion opportunities, supported by ongoing life cycle management.
BridgeBio Pharma Slides: Corporate presentation
BridgeBio Pharma has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for tr...
BridgeBio Pharma Transcript: Bank of America Global Healthcare Conference 2026
Strong commercial momentum is driven by Attruby’s differentiation in efficacy, safety, and convenience, with robust pipeline launches expected to add significant revenue. Recent IP clarity and real-world data support confidence in achieving peak sales targets, while launch readiness is underpinned by experienced leadership and expanding patient identification efforts.
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p
BridgeBio Pharma Earnings Call Transcript: Q1 2026
Q1 2026 delivered robust revenue growth, led by Attruby's blockbuster trajectory and expanding market share. Three major launches are on track, supported by strong clinical data and commercial readiness. A $500M share buyback was authorized, reflecting confidence in long-term value.
BridgeBio Pharma Earnings release: Q1 2026
BridgeBio Pharma released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
BridgeBio Pharma Quarterly report: Q1 2026
BridgeBio Pharma has published its Q1 2026 quarterly earnings report on May 7, 2026.
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
PALO ALTO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on develop...